{"disease":{"id":"musk-myasthenia-gravis","name":"musk myasthenia gravis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06259071","title":"MuSK Myasthenia 1000 Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Myasthenia Gravis Rare Disease Network","has_results":false},{"nct_id":"NCT03579966","title":"Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":63,"lead_sponsor_name":"Catalyst Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05451212","title":"Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Cabaletta Bio","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}